The effect of a single dose of enoxaparine on the angiogenic potential of human serum and plasma

Central-European Journal of Immunology

Volumn 33, Issue 2, 2008, Pages 50-53

  Jung, Leszek ^a   Chorostowska Wynimko, Joanna ^b   Skopińska Rózewska, Ewa ^c   Siwicki, Andrzej K ^d   Skorupski, Marcin ^a   Sommer, Ewa ^c   Bałan, Barbara J ^c   Rozy, Adriana ^b   Wasiutyński, Aleksander ^c  

^a INSTITUTE OF RHEUMATOLOGY   (Poland)

^b NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

Angiogenesis; AT III; Enoxaparine; Fibrinogen; IGF 1; PAI 1; VEGF

Indexed keywords

ANTITHROMBIN III; ENOXAPARIN; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOMATOMEDIN C; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HIP SURGERY; HUMAN; MALE; SINGLE DRUG DOSE;

EID: 44449171948     PISSN: 14263912     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Folkman J, Taylor S, Spillberg C (1983): The role of heparin in angiogenesis. Ciba Found Symp 100: 132-149.
2. Jung L, Skopińska-Różewska E, Małdyk P et al. (2006): Enoxaparine treatment enhanced angiogenic activity of mouse and human serum. Centr Eur J Immunol 31: 6-10.
3. Yamazaki Y, Morita T (2006): Molecular and functional diversity of vascular endothelial growth factors. Mol Divers 10: 515-527.
4. Sisson TH, Simon R (2004): Cell specific control of coagulation and fibrinolysis within the lung. Thromb Haemost 92: 435-437.
5. Chorostowska-Wynimko J, Skrzypczak-Jankun E, Jankun J (2004): Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis (Review). Int J Mol Med 13: 759-766.
6. Skopinski P, Szaflik J, Duda-Król B et al. (2004): Suppression of angiogenic activity of sera from diabetic patients with non-proliferative retinopathy by compounds of herbal origin and sulindac sulfone. Int J Mol Med 14: 707-711.
7. Barcz E, Różewska ES, Kaminski Pet al. (2002): Angiogenic activity and IL-8 concentrations in peritoneal fluid and sera in endometriosis. Int J Gynaecol Obstet 79: 229-235.
8. Norman D, Miller Y, Sabo E et al. (2002): The effects of enoxaparin on reparative processes in experimental osteonecrosis of the femoral head of the rat. APMIS 110: 221-228.
9. East MA, Landis DI, Thompson MA, Annex BH (2003): Effect of single dose of intravenous heparin on plasma levels of angiogenic growth factors. Am J Cardiol 91: 1234-1236.
10. Khorana AA, Sahni A, Altland OD, Francis CW (2003): Heparin inhibition of endothelial cells proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 23: 2110-2115.
11. Bierhaus A, Nawroth PP (2004): Antiangiogenic properties of low molecular weight heparin - does tissue factor provide the answer. Thromb Haemost 92: 438-439.
12. Norrby K (2006): Low-molecular-weight heparins and angiogenesis. APMIS 114: 79-102.
13. Smorenburg SM, Van Noorden CJ (2001): The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53: 93-105.
14. Niers TM, Klerk CP, Dinisio M et al. (2007): Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 61: 195-207.
15. Mnich Z, Palka J (2001): Heparin-induced modulation of insulin like growth factor-I action on glucose level in control and fasted rats. Med Sci Monit 7: 42-48.
16. Sorrell AM, Shand JH, Tonner E et al. (2006): Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-1 or heparin. J Biol Chem 281: 10883-10889.